Physician profile
Veronica C Davis
NPI 1770743015
$6,668.38
in general payments reported to CMS, 2019-2025
34 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $736 · 2021: $860 · 2022: $978 · 2023: $1,053 · 2024: $990 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,848.21 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $971.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $467.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $332.62 | 2021-2025 | Qulipta |
| Abbott Laboratories | $300.77 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.84 | 2019-2023 | Synjardy, Jardiance |
| Dexcom, INC. | $161.49 | 2020-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $145.15 | 2019-2025 | |
| Pfizer INC. | $105.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $100.57 | 2019-2025 | Shingrix, Bexsero, Rotarix |
| Bayer Healthcare Pharmaceuticals INC. | $96.37 | 2022-2024 | |
| Cranial Technologies, INC | $95.48 | 2019-2023 | Doc Band |
| Merck Sharp & Dohme LLC | $95.04 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Amgen INC. | $94.22 | 2019-2025 | Repatha, Otezla |
| Currax Pharmaceuticals LLC | $60.72 | 2020-2025 | Contrave |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $52.85 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $51.94 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.18 | 2022 | |
| Sanofi Pasteur INC. | $35.10 | 2019-2023 | |
| Insmed, INC. | $30.89 | 2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $30.51 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.58 | 2022 | |
| Sequel Med Tech, LLC | $25.05 | 2025 | Twiist |
| Verrica Pharmaceuticals INC. | $23.63 | 2024 | Ycanth |
| Amarin Pharma, INC. | $23.57 | 2022 | |
| Corcept Therapeutics | $23.17 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $23.09 | 2025 | Zoryve |
| Upsher-Smith Laboratories LLC | $20.43 | 2020 | |
| Idorsia Pharmaceuticals US INC | $19.40 | 2023 | Quviviq |
| Insulet Corporation | $18.58 | 2021 | |
| Distalmotion US | $17.79 | 2025 | Dexter L6 Robot |
| Supernus Pharmaceuticals, INC. | $14.66 | 2021 | |
| Exact Sciences Corporation | $14.61 | 2025 | Cologuard Collection Kit |
| Shire North American Group INC | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.